Modern Slavery Statement

Purpose of this statement

Consilient Health Limited and its subsidiaries (collectively referred to as “Consilient Health”) are committed to preventing modern slavery and human trafficking in our business and our supply chain. This statement constitutes Consilient Health’s modern slavery and human trafficking statement pursuant to Section 54(1) of the Modern Slavery Act 2015.

Overview of our business

Consilient Health is a mid-sized pharmaceutical company with a strong heritage of commercialising differentiated and niche products in complex markets.

Founded in 2005, our success has been driven by developing strong partnerships with pharmaceutical companies, ensuring market access, and effectively marketing and distributing their prescription healthcare products in the UK and Europe.

We carefully evaluate and prioritise products that are differentiated and have the potential to address clear unmet clinical needs.

As an equal opportunities employer, we are committed to ensuring there is no form of forced labour, including modern slavery and human trafficking, in any part of our business or supply chains.

Our policies

Consilient Health has a number of policies and procedures which are relevant for mitigating the risk of slavery or human trafficking happening in our business or our supply chains. These include:

  • A Code of Conduct, applicable to all parts of Consilient Health;
  • An Anticorruption and Bribery policy;
  • Robust Disciplinary and Grievance policies;
  • An Equal Opportunities and Dignity at Work policy;
  • Clear Recruitment Policy and Procedures; and
  • A Whistleblowing Policy that facilitates staff in reporting suspected wrongdoing (including concerns that may relates to modern slavery
    and human trafficking).
  • In addition, Openness and Honesty is one of our core competencies and forms a part of every employee’s performance management
    process.

Our supply chain

Consilient Health has longstanding relationships with many of our suppliers and partners. We expect our suppliers and partners to adopt standards aimed at preventing modern slavery and human trafficking, similar to those we adhere to, throughout their businesses. We will strive to only work with those parties who comply with these standards and who will deal with issues of non-compliance appropriately.

We undertake all reasonable and practical steps to ensure that suppliers and partners meet our expectations of good human rights practices and general business ethics, and to help identify opportunities to reduce the risk of forced labour within our supply chain.

Awareness and training

Our Modern Slavery statement has been communicated to all our staff and is included as part of our new employees’ induction & training plan. It is the responsibility of all employees to adhere to the statement.

We encourage all employees to be vigilant and report any suspicions of any acts or behaviours which may contradict this statement to their Manager. Any employee who fails to comply with this statement will face disciplinary action up to and including dismissal.

Consilient Health will continue to provide awareness training to staff on the Modern Slavery Act 2015 ensuring they are aware of the appropriate action to take if they suspect slavery or human trafficking. As part of the company’s on-going development we may also review or consider additional policies, procedures or requirements, if appropriate.

Performance monitoring

We undertake a range of measures to monitor the effectiveness of the steps that we are taking to ensure that slavery and/or human trafficking is not taking place within our business or supply chain, including:

  • Regular engagement with and review of relationships with our suppliers and business partners;
  • Ensuring employees are aware of Consilient Health’s policies and keep up-to-date with any changes; and
  • Regular review of our policies and procedures.

Approval

This statement was approved by John Fagan, Finance Director, on behalf of Consilient Health on 28 July 2025. The statement will be reviewed and updated as appropriate on an annual basis.

CORP-CH-1660gc(1) July 2025